Targeting sphingolipid metabolism in chronic lymphocytic leukemia
Clinical and Experimental Medicine · 2024
DOI: 10.1007/s10238-024-01440-x ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Medicine, 2024. Verfasst von Flora Nguyen Van Long und 7 weiteren Autor:innen. Beteiligte Einrichtung: Centre Hospitalier Universitaire (CHU) de Québec Research Center, Faculty of Pharmacy and Université Laval Cancer Research Center, Université Laval, …. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Sphingolipids, Cell Survival. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Canada Foundation for Innovation, CIHR, Canada Research Chair in Pharmacogenomics.
Abstract (Originalsprache)
Elevated levels of circulating C16:0 glucosylceramides (GluCer) and increased mRNA expression of UDP-glucose ceramide glycosyltransferase ( UGCG ), the enzyme responsible for converting ceramides (Cer) to GluCer, represent unfavorable prognostic markers in chronic lymphocytic leukemia (CLL) patients. To evaluate the therapeutic potential of inhibiting GluCer synthesis, we genetically repressed the UGCG pathway using in vitro models of leukemic B cells, in addition to UGCG pharmacological inhibition with approved drugs such as eliglustat and ibiglustat, both individually and in combination with ibrutinib, assessed in cell models and primary CLL patient cells. Cell viability, apoptosis, and proliferation were evaluated in vitro, and survival and apoptosis were examined ex vivo. UGCG inhibition efficacy was confirmed by quantifying intracellular sphingolipid levels through targeted lipidomics using mass spectrometry. Other inhibitors of sphingolipid biosynthesis pathways were similarly assessed. Blocking UGCG significantly decreased cell viability and proliferation, highlighting the oncogenic role of UGCG in CLL. The efficient inhibition of UGCG was confirmed by a significant reduction in GluCer intracellular levels. The combination of UGCG inhibitors with ibrutinib demonstrated synergistic effect. Inhibitors that target alternative pathways within sphingolipid metabolism, like sphingosine kinases inhibitor SKI-II, also demonstrated promising therapeutic effects both alone and when used in combination with ibrutinib, reinforcing the oncogenic impact of sphingolipids in CLL cells. Targeting sphingolipid metabolism, especially the UGCG pathway, represents a promising therapeutic strategy and as a combination therapy for potential treatment of CLL patients, warranting further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre Hospitalier Universitaire (CHU) de Québec Research Center, Faculty of Pharmacy and Université Laval Cancer Research Center, Université Laval, R4701.5, 2705 Blvd Laurier, Quebec, QC, G1V 4G2, Canada.
- Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
- Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. katrina.vanura@meduniwien.ac.at.
- Centre Hospitalier Universitaire (CHU) de Québec Research Center, Faculty of Pharmacy and Université Laval Cancer Research Center, Université Laval, R4701.5, 2705 Blvd Laurier, Quebec, QC, G1V 4G2, Canada. chantal.guill…
- Canada Research Chair in Pharmacogenomics, Quebec, Canada. chantal.guillemette@crchudequebec.ulaval.ca.
Förderung
- Canada Foundation for Innovation
- CIHR
- Canada Research Chair in Pharmacogenomics
- Canadian Institutes of Health Research
Zitieren
APA
Nguyen Van Long, F., Le, T., Caron, P., Valcourt-Gendron, D., Sergerie, R., Laverdière, I., Vanura, K., & Guillemette, C. (2024). Targeting sphingolipid metabolism in chronic lymphocytic leukemia. Clinical and Experimental Medicine. https://doi.org/10.1007/s10238-024-01440-x
Vancouver
Nguyen Van Long F, Le T, Caron P, Valcourt-Gendron D, Sergerie R, Laverdière I, et al. Targeting sphingolipid metabolism in chronic lymphocytic leukemia. Clinical and Experimental Medicine. 2024. doi:10.1007/s10238-024-01440-x
BibTeX
@article{NguyenVanLong2024,
author = {Nguyen Van Long, Flora and Le, Trang and Caron, Patrick and Valcourt-Gendron, Délya and Sergerie, Roxanne and Laverdière, Isabelle and Vanura, Katrina and Guillemette, Chantal},
title = {Targeting sphingolipid metabolism in chronic lymphocytic leukemia},
journal = {Clinical and Experimental Medicine},
year = {2024},
doi = {10.1007/s10238-024-01440-x}
}
EUVIMED